Back to News
Apr 29, 2026 4:01 PM

Sapho Bio Secures $5M, Advances Rapid Sterility Testing Through USP<1223> Validation

Company secures $5M in funding to accelerate its rapid testing platform

USP(TYO:1223) Validation achieved, reinforcing 20-hour testing method

Faster test results replace the standard 14-day USP sterility test

SAN CARLOS, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- Sapho Bio, a biotechnology company developing a rapid microbiology release platform for precision medicine, announces $5M in secured funding, USP(TYO:1223) Validation, and validated rapid sterility test results. Together, these milestones signal a pivotal inflection point for pharmaceutical manufacturing, replacing a testing standard from decades ago that was not designed for modern therapies.

Sapho Bio's pipeline includes its first commercialized product, a rapid sterility testing service, and a sterility testing kit in development. The company leverages RNA-based detection to identify living bacteria and fungi, delivering results in approximately ...